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OBJECTIVES: The objective is to compare patterns of patient
compliance on a ﬁxed-dose combination therapy (FDCT) versus
single agent combination therapy (SACT) with any newly initi-
ated thiazolidinedione (TZD) and metformin (MET) for the
treatment of diabetes. METHODS: This study utilized a retro-
spective pharmacy claims database of continuously eligible
patients who were newly initiated on a TZD or MET either in
FDCT or SACT. Patients during December 2005 to June 2006
were identiﬁed and followed for six months. Patients who
switched between FDCT and SACTs were excluded. Due to a
national Avandamet shortage spanning July 2005 to June 2006,
patients on Avandamet were excluded resulting in comparison
between Actoplus Met as FDCT and SACT groups. Adherence
was deﬁned as proportion of days covered when both TZD
and MET were available >80% of the time. Propensity-score
weighted logistic regression was used to adjust for patient demo-
graphics and plan characteristics. RESULTS: There were 729 and
19,440 patients on FDCT and SACT respectively. Mean age were
55 and 58 years (P < 0.0001), proportion female were 39% and
43% (P < 0.0362), and prior sulfonylurea utilization rates at
baseline were 30% and 53% (P < 0.0001), respectively. Distri-
bution of the patient population in various market segments
(managed care, Medicaid, Medicare, and Self-Insured) differed.
Unadjusted adherence rates were 51% and 48% for FDCT and
SACT respectively. Adjusting for baseline characteristics, patients
on FDCT were 50% more likely to be adherent to therapy
[OR = 1.50, 95% CI = 1.46–1.55]. CONCLUSION: When con-
trolling for multiple factors, patients on FDCT were more likely
to be adherent to therapy compared to those on SACT.
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OBJECTIVES: Although many studies have examined adherence
to oral anti-hyperglycemic drug (OAD) treatment, they have
generally suffered from their lack at considering different pat-
terns of use, in particular return to therapy after discontinuation.
We assessed persistence patterns with OAD in patients newly
dispensed different OAD classes. METHODS: We conducted a
population-based cohort study using Quebec Health Insurance
Board data. Patients aged 18 years or more newly dispensed an
OAD between January 1, 1998 and December 31, 2003 were
included in the study (n = 100,631). Persistence was deﬁned as
consistently reﬁlling a prescription for the initial OAD within
three times the days’ supply of the preceding claim. For non-
persistent individuals, a second course of therapy was deﬁned as
treatment initiation with any OAD following a ﬁrst discontinu-
ation. Patients were followed from treatment initiation up to
December 31, 2004, ineligibility to the drug plan or death,
whichever comes ﬁrst, and treatment discontinuation or second
course of treatment. Cox regression models were used to
compute adjusted hazards ratios (AHR) of persistence and ini-
tiation of second courses of therapy. RESULTS: Compared to
biguanides, the likelihood of discontinuing the initial OAD over
the study period was signiﬁcantly higher for sulphonylureas
(AHR: 1.32; 95%CI: 1.29–1.34). Patients started on sulphony-
lureas were also less likely to start a second course of therapy
after a ﬁrst treatment discontinuation (AHR: 0.91; 95%CI:
0.89–0.93). Finally, among patients who had started a second
course of therapy, those on sulphonylureas were more likely to
discontinue again (AHR: 1.06; 95% CI: 1.03–1.09). CONCLU-
SION: Compared to diabetic patients initiated on a biguanide,
those initiated on sulphonylureas had both lower persistence to
their treatment and were less likely to initiate a second course of
treatment after discontinuation. They were also more likely to
discontinue again.
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OBJECTIVES: To evaluate the cost effectiveness of a Measure-
ment Guided Medication Management (MGMM) adherence
intervention program intended to prolong persistence of type 2
diabetic patients with metformin as monotherapy. METHODS:
This analysis used a stochastic simulation model wherein each
year a proportion of patients treated with metformin as mono-
therapy develop a need for additional therapy (insulin, sulfony-
lurea, or glitazone) to control their glycemic level. In the absence
of any adherence intervention, the ﬁrst year’s proportion of
patients escalating out of monotherapy was estimated using the
persistence estimate of 863 patients with oral antidiabetic
therapy from the Pharmionic Knowledge Center database. The
subsequent years’ proportions were derived from the UK Pro-
spective Diabetes Study. The impact of intervention was modeled
on the basis of a) published evidence of the statistically signiﬁcant
effectiveness of MGMM in extending persistence; b) the conse-
quences of beta cell deterioration; and c) the side-effects of
metformin. Direct medical costs and health utility values were
derived from published sources. RESULTS: The estimated pro-
portion of patients escalating out of monotherapy by the end of
the ﬁrst year is 44% and 11%/year for the second and subse-
quent years. MGMM-based intervention decreases this propor-
tion by at least 17% for the ﬁrst year and 5%/yr for subsequent
years. When all newly diagnosed patients receive the MGMM-
based intervention, it is cost effective up to a cost of US$1/day per
patient (US$18243/QALY gained). When screening is feasible for
non-response based on glycemic level evolution, MGMM is cost
effective up to US$6/day per patient (US$18506/QALY gained).
CONCLUSION: An MGMM-based intervention program to
lengthen persistence with metformin as monotherapy in Type 2
Diabetes is projected to be cost effective. This intervention is
projected not only to optimize metformin exposure, but also to
improve clinical outcomes, while guiding the allocation of
limited resources, for greatest effectiveness.
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